The choice of antibacterial drugs.
D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D002439:Cefotaxime / Q000627:therapeutic use; D002442:Ceftazidime / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000188:drug therapy; D003365:Costs and Cost Analysis; D003428:Cross Infection / Q000188:drug therapy; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D016983:Enterococcus / Q000187:drug effects; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D018942:Macrolides; D016920:Meningitis, Bacterial / Q000188:drug therapy; D008585:Meningitis, Meningococcal / Q000188:drug therapy; D008586:Meningitis, Pneumococcal / Q000188:drug therapy; D008826:Microbial Sensitivity Tests; D009503:Neutropenia / Q000188:drug therapy; D011008:Pneumococcal Infections / Q000150:complications / Q000188:drug therapy; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D018942:Macrolides; D002442:Ceftazidime; D002439:Cefotaxime